AbbVie skin drug reduces lesions in late stage trial
AbbVie reported its experimental drug lutikizumab met main goals in a late-stage skin disease trial. The company plans to test the treatment alongside a new weight-loss drug by year-end to address related obesity factors.
Xurve View
Insights:
Xurve View
AbbVie announced Thursday that its experimental drug lutikizumab reduced inflammatory skin lesions by at least 75% in 31% of patients during a late-stage study. The trial tested 1,400 patients suffering from hidradenitis suppurativa, a chronic condition causing painful lumps under the skin.
